Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Forbindelser med formel (I): Medikamenter. N-[3-Hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide (I), its enantiomers and base addition salts, are new. N-[3-Hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide of formula (I), its enantiomers and base addition salts, are new. An independent claim i...

Full description

Saved in:
Bibliographic Details
Main Authors CAIGNARD DANIEL-HENRI, PERES BASILE, SPEDDING MICHAEL, MILLAN MARK, BERTHELOT PASCAL, SABAOUNI AHMED, DELAGRANGE PHILIPPE, YOUS SAID
Format Patent
LanguageNorwegian
Published 02.01.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Forbindelser med formel (I): Medikamenter. N-[3-Hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide (I), its enantiomers and base addition salts, are new. N-[3-Hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide of formula (I), its enantiomers and base addition salts, are new. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Hypnotic; Tranquilizer; Antidepressant; Cardiovascular-Gen; Gastrointestinal-Gen; Neuroleptic; Anorectic; Anticonvulsant; Antidiabetic; Antiparkinsonian; Nootropic; Antimigraine; Neuroprotective; Cerebroprotective; Contraceptive; Endocrine-Gen; Immunomodulator; Cytostatic. MECHANISM OF ACTION : Melatonin receptor binder. The ability of (I) to bind with melatonin was tested. The results showed that N-[3-hydroxy-2-(7-methoxy-1-naphthyl)propyl] propanamide exhibited an inhibition constant value of 1.4 nM and 3.2 nM to bind with melatonin receptors MT 1 and MT 2, respectively.
Bibliography:Application Number: NO20070003295